头孢他啶-阿维巴坦（Avycaz）：用于治疗复杂性腹腔内感染和泌尿道感染。
Ceftazidime-Avibactam (Avycaz): For the Treatment of Complicated Intra-Abdominal and Urinary Tract Infections.
作者信息
Mosley Juan F, Smith Lillian L, Parke Crystal K, Brown Jamal A, Wilson Alton L, Gibbs Lydia V
出版信息
P T. 2016 Aug;41(8):479-83.
Abstract
Ceftazidime-avibactam (Avycaz) for the treatment of complicated infections.
摘要
头孢他啶-阿维巴坦（Avycaz）用于治疗复杂性感染。
相似文献
1
2
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.头孢他啶-阿维巴坦或最佳现有治疗在头孢他啶耐药肠杆菌科和铜绿假单胞菌引起的复杂性尿路感染或复杂性腹腔内感染患者中的应用（REPRISE）：一项随机、针对病原体的 3 期研究。
Lancet Infect Dis. 2016 Jun;16(6):661-673. doi: 10.1016/S1473-3099(16)30004-4. Epub 2016 Apr 20.
3
Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.头孢他啶-阿维巴坦用于治疗复杂性尿路感染和复杂性腹腔内感染。
Expert Rev Clin Pharmacol. 2015;8(6):691-707. doi: 10.1586/17512433.2015.1090874. Epub 2015 Sep 30.
4
Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections.关注头孢他啶-阿维巴坦以优化复杂性腹腔内感染和尿路感染的治疗效果。
Expert Opin Investig Drugs. 2015;24(9):1261-73. doi: 10.1517/13543784.2015.1062873. Epub 2015 Jul 6.
5
Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia.头孢他啶-阿维巴坦在成人复杂性腹腔内感染、复杂性尿路感染和医院获得性肺炎中的剂量选择和验证。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02187-18. Print 2019 Apr.
6
Efficacy and safety of ceftazidime-avibactam in the treatment of complicated intra-abdominal infections (CIAIs) and complicated urinary tract infections (CUTIs): A meta-analysis of randomized controlled trials.头孢他啶-阿维巴坦治疗复杂性腹腔内感染（CIAIs）和复杂性尿路感染（CUTIs）的疗效与安全性：一项随机对照试验的荟萃分析。
Rev Assoc Med Bras (1992). 2018 Mar;64(3):253-263. doi: 10.1590/1806-9282.64.03.253.
7
In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens.头孢他啶-阿维巴坦对头孢他啶不敏感革兰阴性病原菌所致复杂性腹腔内感染和尿路感染3期开放标签临床试验中分离株的体外活性
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01820-16. Print 2017 Feb.
8
In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.头孢他啶/阿维巴坦对治疗复杂性尿路感染3期临床试验项目中患者尿液分离株的体外活性。
J Antimicrob Chemother. 2017 May 1;72(5):1396-1399. doi: 10.1093/jac/dkw561.
9
Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.头孢他啶-阿维巴坦：一种用于治疗耐药革兰氏阴性菌的新型头孢菌素/β-内酰胺酶抑制剂组合
Clin Ther. 2016 Mar;38(3):431-44. doi: 10.1016/j.clinthera.2016.01.018. Epub 2016 Mar 2.
10
Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections.头孢他啶-阿维巴坦（CTZ-AVI）用于治疗成年住院复杂性腹腔内感染患者。
Expert Rev Anti Infect Ther. 2016;14(5):451-63. doi: 10.1586/14787210.2016.1173542.
引用本文的文献
1
Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations.由于噬菌体与临床可达到浓度的抗生素之间的体外协同相互作用，多重耐药产碳青霉烯酶肺炎克雷伯菌临床分离株的表型耐药性得以逆转。
J Antimicrob Chemother. 2025 Jul 1;80(7):1997-2006. doi: 10.1093/jac/dkaf163.
2
7--Carboxylic Acid-Substituted 3--Alkyl Difluoroquercetin; An Aztreonam-Potentiating Agent Against Carbapenemase-Producing Through Simultaneous Inhibition of Metallo-β-Lactamase and Efflux Pump.7-羧酸取代的3-烷基二氟槲皮素；一种通过同时抑制金属β-内酰胺酶和外排泵来增强氨曲南对产碳青霉烯酶菌活性的药物。
Antibiotics (Basel). 2024 Dec 10;13(12):1202. doi: 10.3390/antibiotics13121202.
3
Effect of Ceftaroline, Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam on Establishment of Colonization by Vancomycin-Resistant Enterococci and in Mice.头孢洛林、头孢他啶/阿维巴坦、头孢托罗/他唑巴坦和美罗培南/瓦博巴坦对耐万古霉素肠球菌在小鼠体内定殖的影响
Pathog Immun. 2024 Sep 24;9(2):194-204. doi: 10.20411/pai.v9i2.711. eCollection 2024.
4
Peptide-mimetic treatment of Pseudomonas aeruginosa in a mouse model of respiratory infection.肽模拟物治疗呼吸道感染小鼠模型中的铜绿假单胞菌。
Commun Biol. 2024 Aug 22;7(1):1033. doi: 10.1038/s42003-024-06725-1.
5
Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review.朋友还是敌人？应对多重耐药/广泛耐药革兰氏阴性菌的新型抗菌药物：一项系统综述
Front Microbiol. 2024 May 10;15:1385475. doi: 10.3389/fmicb.2024.1385475. eCollection 2024.
6
Evaluation of the stability of ceftazidime/avibactam in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy utilizing a national stability protocol framework.利用国家稳定性协议框架评估头孢他啶/阿维巴坦在用于门诊胃肠外抗菌治疗的弹性输液装置中的稳定性。
JAC Antimicrob Resist. 2024 Apr 5;6(2):dlae056. doi: 10.1093/jacamr/dlae056. eCollection 2024 Apr.
7
Antibiotic adjuvants: synergistic tool to combat multi-drug resistant pathogens.抗生素佐剂：应对多重耐药病原体的协同工具。
Front Cell Infect Microbiol. 2023 Dec 20;13:1293633. doi: 10.3389/fcimb.2023.1293633. eCollection 2023.
8
Integrated Transcriptomic and Metabolomic Mapping Reveals the Mechanism of Action of Ceftazidime/Avibactam against Pan-Drug-Resistant .综合转录组学和代谢组学图谱揭示头孢他啶/阿维巴坦对泛耐药的作用机制。
ACS Infect Dis. 2023 Dec 8;9(12):2409-2422. doi: 10.1021/acsinfecdis.3c00264. Epub 2023 Oct 25.
9
Cost-Effectiveness of Short Course of Ceftazidime/Avibactam for -KPC Bloodstream Infections in Italy.意大利短疗程头孢他啶/阿维巴坦治疗产KPC血流感染的成本效益分析
Microorganisms. 2023 Apr 23;11(5):1102. doi: 10.3390/microorganisms11051102.
10
Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients.头孢他啶-阿维巴坦、头孢洛扎-他唑巴坦、头孢地尔、新型达罗巴坦类似物对儿科和青少年囊性纤维化患者多药耐药铜绿假单胞菌分离株的抗菌活性。
Microbiol Spectr. 2023 Feb 14;11(1):e0443722. doi: 10.1128/spectrum.04437-22. Epub 2023 Jan 24.
本文引用的文献
1
Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria.新型抗革兰氏阴性菌抗菌药物的研究进展
Microbiol Insights. 2016 Mar 20;9:9-19. doi: 10.4137/MBI.S29459. eCollection 2016.
2
Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes.碳青霉烯类耐药肠杆菌科细菌：治疗与结局的综述。
Diagn Microbiol Infect Dis. 2013 Feb;75(2):115-20. doi: 10.1016/j.diagmicrobio.2012.11.009. Epub 2013 Jan 3.
Zotero 插件